{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:52:19Z","timestamp":1793656339357,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40487-022-00211-6","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T21:53:39Z","timestamp":1669758819000},"page":"65-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Peter","family":"Borchmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-2793","authenticated-orcid":false,"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Papadimitrious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"16","key":"211_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"key":"211_CR2","unstructured":"Gemeinsamer Bundesauschuss. Nutzenbewertungsverfahren zum Wirkstoff Polatuzumab Vedotin, 2020, available: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/518\/#dossier"},{"issue":"1","key":"211_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma. 2022;63(1):54\u201363.","journal-title":"Leuk Lymphoma"},{"key":"211_CR4","doi-asserted-by":"crossref","unstructured":"Moertl B, Dreyling M, Schmidt C at al. Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective. Clin Lymphoma Myeloma Leuk. 2022,22(7):474\u2013482.","DOI":"10.1016\/j.clml.2021.12.018"},{"issue":"1","key":"211_CR5","first-page":"25","volume":"88","author":"AB Daly","year":"2019","unstructured":"Daly AB, Cuthbert R, Finnegan D, et al. A comparison of inpatient and outpatient-based chemotherapy regimens for the treatment of acute myeloid leukaemia in the elderly. Ulster Med J. 2019;88(1):25\u20139.","journal-title":"Ulster Med J"},{"key":"211_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s005200000224","volume":"9","author":"G Egerer","year":"2001","unstructured":"Egerer G, Hegenbart U, Salwender H, et al. Outpatient treatment of multiple myeloma with a combination of vincristine. Adriamycin and dexamethasone Support Care Cancer. 2001;9:380\u20135.","journal-title":"Adriamycin and dexamethasone Support Care Cancer"},{"key":"211_CR7","doi-asserted-by":"crossref","unstructured":"Gordan L, Blazer M, Saundankar V et al. Cost Differences associated with oncology care delivered in a community setting versus a hospital setting: a matched-claims analysis of patients with breast, colorectal, and lung cancers. J Oncol Pract 2018:JOP1700040.","DOI":"10.1200\/JOP.17.00040"},{"issue":"11\u201312","key":"211_CR8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1159\/000509973","volume":"104","author":"M B\u00f6gemann","year":"2020","unstructured":"B\u00f6gemann M, Zagorska A, Akumo D, et al. Using data from a sickness fund claims database to assess the treatment patterns and healthcare resource utilization among patients with metastatic renal cell carcinoma in Germany. Urol Int. 2020;104(11\u201312):982\u201393.","journal-title":"Urol Int"},{"issue":"1","key":"211_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40261-020-00990-8","volume":"41","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, Olbrich K, Wilk A, et al. Time to treatment discontinuation in German patients with schizophrenia: long-acting injectables versus oral antipsychotics. Clin Drug Investig. 2021;41(1):99\u2013113.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"211_CR10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s12325-019-00969-8","volume":"36","author":"J Mahlich","year":"2019","unstructured":"Mahlich J, Alba A, El Hadad L, et al. Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis. Adv Ther. 2019;36(7):1684\u201399.","journal-title":"Adv Ther"},{"issue":"8","key":"211_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237509","volume":"15","author":"S Tsutsu\u00e9","year":"2020","unstructured":"Tsutsu\u00e9 S, Tobinai K, Yi J, et al. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS ONE. 2020;15(8): e0237509.","journal-title":"PLoS ONE"},{"issue":"1","key":"211_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","volume":"110","author":"J Armitage","year":"2007","unstructured":"Armitage J. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29\u201336.","journal-title":"Blood"},{"key":"211_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"211_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","volume":"137","author":"Y Kobayashi","year":"2011","unstructured":"Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011;137:1079\u201384.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"211_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/jcm9041005","volume":"9","author":"F Kocher","year":"2020","unstructured":"Kocher F, Mian M, Seeber A, et al. The prognostic impact of comorbidities in patients with de-novo diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy in curative intent. J Clin Med. 2020;9(4):1005.","journal-title":"J Clin Med"},{"issue":"7","key":"211_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1080\/10428194.2020.1734592","volume":"61","author":"J Tkacz","year":"2020","unstructured":"Tkacz J, Garcia J, Gitlin M, et al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk Lymphoma. 2020;61(7):1601\u20139.","journal-title":"Leuk Lymphoma"},{"key":"211_CR17","doi-asserted-by":"crossref","unstructured":"Yang X, Lalibert\u00e9 F, Germain G et al. Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S. Oncologist. 2021;26(5):e817-e826.","DOI":"10.1002\/onco.13721"},{"issue":"9","key":"211_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","volume":"24","author":"A Purdum","year":"2019","unstructured":"Purdum A, Tieu R, Reddy SR, et al. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229\u201336.","journal-title":"Oncologist"},{"key":"211_CR19","doi-asserted-by":"crossref","unstructured":"Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncology 2018 10;14(25):2627\u20132642.","DOI":"10.2217\/fon-2018-0267"},{"key":"211_CR20","doi-asserted-by":"crossref","unstructured":"Ren J, Asche CV, Shou Y, et al. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. Journal of Comparative Effectiveness Research 2019 4;8(6):393\u2013402","DOI":"10.2217\/cer-2018-0094"},{"key":"211_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0167-6296(99)00039-9","volume":"19","author":"PM Danzon","year":"2000","unstructured":"Danzon PM, Chao L-W. Cross-national price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19:159\u201395.","journal-title":"J Health Econ"},{"key":"211_CR22","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1377\/hlthaff.2010.0204","volume":"30","author":"M Laugesen","year":"2011","unstructured":"Laugesen M, Glied S. Higher fees paid to US physicians drive higher spending for physician services compared to other countries. Health Aff (Millwood). 2011;30:1647\u201356.","journal-title":"Health Aff (Millwood)"},{"key":"211_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.puhe.2016.06.023","volume":"141","author":"A Rump","year":"2016","unstructured":"Rump A, Sch\u00f6ffski O. The German and Japanese health care systems: an international comparison using an input-output model. Public Health. 2016;141:63\u201373.","journal-title":"Public Health"},{"issue":"2","key":"211_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10198-016-0775-4","volume":"18","author":"HI Wang","year":"2017","unstructured":"Wang HI, Smith A, Aas E, et al. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. Eur J Health Econ. 2017;18(2):255\u201367.","journal-title":"Eur J Health Econ"},{"issue":"12","key":"211_CR25","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1080\/10428194.2018.1459613","volume":"59","author":"S Huntington","year":"2018","unstructured":"Huntington S, Keshishian A, McGuire M, et al. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk Lymphoma. 2018;59(12):2880\u20137.","journal-title":"Leuk Lymphoma"},{"key":"211_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.zefq.2016.10.004","volume":"118","author":"J Czwikla","year":"2016","unstructured":"Czwikla J, Domhoff D, Giersiepen K. ICD coding quality for outpatient cancer diagnoses in SHI claims data. Z Evid Fortbild Qual Gesundh wesen. 2016;118:48\u201355.","journal-title":"Z Evid Fortbild Qual Gesundh wesen"},{"key":"211_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01736-w","author":"C Scheid","year":"2022","unstructured":"Scheid C, Kudernatsch R, Eckart M, et al. Incidence of graft-versus-host-disease in Germany: evidence from health care claims data. J Public Health. 2022. https:\/\/doi.org\/10.1007\/s10389-022-01736-w.","journal-title":"J Public Health"},{"key":"211_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00320-8","author":"C Scheid","year":"2022","unstructured":"Scheid C, Kudernatsch R, Eckart M, et al. Treatment pathways and health outcomes of German patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a retrospective health claims data analysis. Drugs - Real World Outcomes. 2022. https:\/\/doi.org\/10.1007\/s40801-022-00320-8.","journal-title":"Drugs - Real World Outcomes"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-022-00211-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00211-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:18:30Z","timestamp":1676549910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-022-00211-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s40487-022-00211-6","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}